CellMax Life is a molecular diagnostics company revolutionizing early cancer detection with a proprietary bio-mimetic technology platform that enables detection of pre-cancer & cancer cells in blood. The company's flagship FirstSight Colon-Cancer Screening blood test can detect precancerous colorectal polyps with high sensitivity before they progress to cancer, and was recently granted Breakthrough Device Designation by the US FDA.

CellMax Life was founded in 2013 and is based in California, United States and Nangang software park, Taipei, Taiwan, started by licensing technology from Academia-Sinica, and investors include leading firms in US, Taiwan and Japan. CellMax Life is built on a team of experts across multiple disciplines, including precancer and cancer cell capture and imaging, NGS, algorithm development, biostatistics, and development and commercialization of clinical grade tests.